1443019-04-2

Basic information

• Product Name: trans-4-[([1-(2,3-dihydro-1-benzofuran-5-yl)ethyl]{4-[2-(2,5-dioxo-pyrrolidin-1-yl)ethoxy]-3-methoxy-benzyl}amino)methyl]cyclohexanecarboxylic acid
• Synonyms: trans-4-[([1-(2,3-dihydro-1-benzofuran-5-yl)ethyl]{4-[2-(2,5-dioxo-pyrrolidin-1-yl)ethoxy]-3-methoxy-benzyl}amino)methyl]cyclohexanecarboxylic acid
• CAS NO: 1443019-04-2
• Molecular Weight: 564.679
• Mol File: 1443019-04-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: trans-4-[([1-(2,3-dihydro-1-benzofuran-5-yl)ethyl]{4-[2-(2,5-dioxo-pyrrolidin-1-yl)ethoxy]-3-methoxy-benzyl}amino)methyl]cyclohexanecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: trans-4-[([1-(2,3-dihydro-1-benzofuran-5-yl)ethyl]{4-[2-(2,5-dioxo-pyrrolidin-1-yl)ethoxy]-3-methoxy-benzyl}amino)methyl]cyclohexanecarboxylic acid(1443019-04-2)
• EPA Substance Registry System: trans-4-[([1-(2,3-dihydro-1-benzofuran-5-yl)ethyl]{4-[2-(2,5-dioxo-pyrrolidin-1-yl)ethoxy]-3-methoxy-benzyl}amino)methyl]cyclohexanecarboxylic acid(1443019-04-2)

Safety Data

• Hazardous Substances Data: 1443019-04-2(Hazardous Substances Data)

Upstream product

• 90843-31-5 1-(2,3-dihydrobenzofuran-5-yl)ethanone 
• 7149-10-2 vanillylamine hydrochloride 
• 130972-89-3 (4-hydroxy-3-methoxybenzyl)carbamic acid tert-butyl ester 
• 1443021-37-1 4-[2-(2,5-dioxo-pyrrolidin-1-yl)-ethoxy]-3-methoxy-benzaldehyde 
• 55943-72-1 N-(2-bromoethyl)-succinimide 
• 121-33-5 vanillin 
• 1443021-68-8 1-{2-[4-({[1-(2,3-dihydrobenzofuran-5-yl)ethyl]amino}methyl)-2-methoxyphenoxy]ethyl}pyrrolidine-2,5-dione 
• 99070-23-2 4-(2-bromo-ethoxy)-3-methoxy-benzaldehyde 

Downstream Products

• 1443019-12-2 trans-4-[([(R)-1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-1-yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid 
• 1443019-16-6 trans-4-[([(S)-1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-1-yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid 

Relevant articles and documents

I. Discovery of a novel series of CXCR3 antagonists. Multiparametric optimization of N,N-disubstituted benzylamines

N,N-Disubstituted benzylamine derivatives have been identified as CXCR3 antagonists. Compounds were optimized to improve affinity and selectivity, to increase metabolic stability in human and mouse liver microsomes, to increase Caco-2 permeability. Optimization was supported by monitoring physico-chemical properties using both experimental and computational means. Several compounds with double-digit nanomolar CXCR3 affinity, favorable selectivity, microsomal stability, Caco-2 permeability and human hepatocyte clearance have been identified.

Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists

The present invention relates to compounds of formula 1 that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines. The invention relates furthermore to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to the novel intermediates used in the preparation of said compounds.